Catheter Precision, Inc. 8-K

What Happened
Catheter Precision, Inc. announced the closing on July 15, 2026 of the sale and issuance of 3,470 shares of newly designated Series C-3 Convertible Preferred Stock for aggregate gross proceeds of $3,470,000. The issuance followed prior Securities Purchase Agreements (filed Feb. 6 and Mar. 9, 2026), stockholder approval obtained April 15, 2026, and effectiveness of a related Form S-1 registration statement declared effective by the SEC on July 10, 2026. The Certificate of Designation for the Series C-3 was filed with Delaware on July 14, 2026.

Key Details

• Gross proceeds: $3,470,000 from issuance of 3,470 shares of Series C-3 Preferred (stated value $1,000/share).
• Conversion terms: initial conversion price $0.632 per share of common stock; conversion floor $0.35/share (company may waive); customary anti-dilution adjustments apply.
• Beneficial ownership limit: conversions are subject to a 4.99% cap of outstanding common stock (holder may increase to 9.99% with 61 days’ prior notice).
• Rights and ranking: Series C-3 ranks senior to common stock for dividends and liquidation; conversion will dilute existing common holders. Placement agent: Dawson James Securities; intended uses: working capital, loan repayment, general corporate purposes.

Why It Matters
The company raised $3.47M through a preferred-stock financing that adds senior-preference equity and will increase potential share count if converted, which can dilute current common shareholders. Investors should note the conversion price and ownership caps (which limit immediate large conversions), the registration of shares issuable upon conversion (Form S-1 effective July 10, 2026), and that proceeds are earmarked for working capital and debt repayment rather than operational expansion. These facts affect capitalization, potential dilution, and the company’s near-term cash position.